<DOC>
	<DOC>NCT03055312</DOC>
	<brief_summary>Compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast</brief_summary>
	<brief_title>Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>This is a phase III,Multi-center,prospective,randomized clinical trials. The objective compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast cancer.Primary endpoint is 16-week clinical benefit rate (CBR).By centre randomized grouping bicalutamide (experimental Group) or TPC (Control Group).</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Age: 1870 years old, female Eastern Cooperative Oncology Group (ECOG) 0 or 1 Confirmed by pathology or organizing cytology AR positive(IHC：≧10%)triple negative breast cancer For the first time recurrence or newly diagnosed advanced breast cancer,Diseasefree survival time 12 months above Measurable disease per RECIST version 1.1,or immeasurably lesions bone metastasis After Recurrence has not received cancer treatment Life expectancy of at least 6 months Signed and dated an informed consent form ECOG score ≧2 Only brain metastasis or meningeal metastasis Receiving other antitumor treatment Heart,lung,liver,kidney,bone marrow,and other functions badness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>